Refine your search

Clear

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease

This is a phase 2/3, multi-center, randomized, double-blind, study for patients with moderate to severe Crohn's disease. Subjects with refractory CD or who are intolerant to at least one current therapy will be considered. The study consists of four substudies. They are designed to investigate efficacy, safety, tolerability of etrasimod as therapy for CD.
Zvjezdana (stella) Sever Chroneos at zchroneos1@pennstatehealth.psu.edu or 717-531-8259
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04173273
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 18-80 years
Crohn's disease >3 months
Inadequate response, LOR or intolerance to more than one therapies
Females must not be/intent to be pregnant
Exclusion Criteria:
History of inadequate response to more than two biologics
Use of certain therapies less than 2 weeks prior to randomization
Hypersensitivity to Entrasimod
Have UC diagnosis
Has infection
Digestive Systems & Liver Disease
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA